This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.

This product is a second-generation sulfonylurea oral hypoglycemic drug. Its main mechanism of hypoglycemic effect is to stimulate pancreatic beta cells to secrete insulin and partially increase the sensitivity of surrounding tissues to insulin. This product binds to and dissociates from insulin receptors faster than glibenclamide and is less likely to cause severe hypoglycemia.

This product is a formylated derivative of the reduced form of folic acid, which is the activated form of folic acid in the body. It can directly provide the activated form of folic acid in the body, which can "rescue" the toxic reaction of excessive folic acid antagonists in the body, and is beneficial to the synthesis of thymine nucleotides, DNA, RNA and even proteins. It can limit the degree of damage of methotrexate to normal cells, and through mutual competition, it can reverse the reaction of methotrexate to the bone marrow and gastrointestinal mucosa, but it has no effect on the existing methotrexate neurotoxicity.

This product can protect the gastric mucosa and slightly inhibit gastric acid secretion.